Drug Profile
Research programme: endothelin B receptor antagonists - ENB Therapeutics
Alternative Names: ENB 002; ETBR blocker - ENB TherapeuticsLatest Information Update: 07 May 2020
Price :
$50
*
At a glance
- Originator ENB Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Endothelin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 07 May 2020 Discontinued - Preclinical for Malignant melanoma in USA (Parenteral)
- 01 Sep 2016 Preclinical trials in Malignant melanoma in USA (Parenteral)